We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+6.52%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$517M
AUM Growth
+$19.8M
Cap. Flow
-$2.75M
Cap. Flow %
-0.53%
Top 10 Hldgs %
81.3%
Holding
59
New
10
Increased
8
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.15M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.53M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.84M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$2.56M
5
SLNO
Soleno Therapeutics
SLNO
+$2.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$16.5M
2
ARGX icon
argenx
ARGX
+$7.31M
3
CYTK icon
Cytokinetics
CYTK
+$6.28M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.34M
5
INSM icon
Insmed
INSM
+$2.51M

Sector Composition

Rank Sector Weight
1 Healthcare 75.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
51
Immunovant
IMVT
$7.91B
– –
-21,397
Closed -$691K
JANX icon
52
Janux Therapeutics
JANX
$934M
– –
-47,949
Closed -$1.81M
MGNX icon
53
MacroGenics
MGNX
$243M
– –
-64,007
Closed -$942K
RAPT
54
DELISTED
RAPT Therapeutics
RAPT
– –
-17,164
Closed -$1.23M
VERA icon
55
Vera Therapeutics
VERA
$2.31B
– –
-24,298
Closed -$1.05M
PSTX
56
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-86,002
Closed -$274K
GRTS
57
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-95,170
Closed -$245K
EFTR
58
CALL
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
– –
-25,000
Closed -$360K
ALPN
59
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-51,714
Closed -$2.05M
1 2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Artia Global Partners held 59 positions worth $517M, up 4% from $498M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners's Q2 2024 filing shows 10 new, 8 increased, 9 reduced and 13 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M. The largest sale was AbbVie, an estimated $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

  • Artia Global Partners's largest Q2 2024 buy was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M.
  • Artia Global Partners added most to Merck in Q2 2024, an estimated $8.15M increase.
  • Artia Global Partners's biggest Q2 2024 reduction was argenx, cutting an estimated $7.31M.
  • Artia Global Partners fully exited AbbVie in Q2 2024, selling an estimated $16.5M.
  • Artia Global Partners's ten largest holdings make up 81% of its $517M portfolio in Q2 2024.
  • Artia Global Partners opened 10 new positions and closed 13 in Q2 2024.
  • Artia Global Partners's portfolio value rose 4% quarter-over-quarter to $517M.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.